HMC explains how convalescent plasma therapy works

Qatar sees a rise in plasma donations from recovered COVID-19 patients

"If you get the call, please donate".

CBC announced Thursday that it now has the capability to conduct the antibody testing. They are responsible for collection of plasma from patients who have recovered from the infection.

Blanchard Valley's outpatient laboratory is working in collaboration with the Mayo Clinic to test for antibodies.

The Mayo Clinic study could influence preventatives like vaccines or treatments for COVID-19 as well as help the study of other diseases. It is also important that donors have fully recovered from COVID-19, and that their body has had time to develop a good antibody response. It's where plasma is taken from a COVID-19 symptom-free, survivor and given to someone who is fighting the virus. "We do not want to give people the idea that they are now protected".

That's why Covenant has teamed up with 2,000 other hospitals, including UT Medical Center, to offer the treatment on a research basis to any patient at their nine medical centers that qualify.

Canadian Blood Services in Charlottetown is hoping Islanders who have had COVID-19 will consider making a plasma donation, as part of a national clinical trial to test whether COVID-19 convalescent plasma could help treat patients with the virus.

Once a person recovers, the antibodies stay in the body to fight the virus if it returns. The trial will generate evidence on whether plasma therapy, the only experimental treatment now available for the virus, can help treat those suffering from acute complications from the virus.

Plasma donation is not the same as blood donation. The process of receiving the plasma takes on average five to seven days. "We have started using plasma treatment at the Communicable Disease Center using plasma from patients who have recovered from COVID-19", said Dr. Muna Al Maslamani, Medical Director, Communicable Disease Center in a television interview recently.

MA biotechnology company Moderna announced Monday that its potential COVID-19 vaccine showed promising early results in clinical trials.



Other news